US2020046833A1PendingUtilityA1
Agonist antibodies that bind human cd137 and uses thereof
Est. expiryJul 11, 2037(~11 yrs left)· nominal 20-yr term from priority
Inventors:Piotr BobrowiczPaul Fredrick WidboomMichael March SchmidtJason M. LajoieRobert V. Tighe, IiiCheuk Lun LeungUgur Eskiocak
A61K 2039/572C07K 16/2818C07K 2317/565C07K 2317/33C07K 2317/75A61P 35/00C07K 16/28C07K 16/2803A61K 39/39558C12N 15/79C07K 2317/34A61K 35/17A61K 39/001117G01N 33/5758G01N 2333/70578A61K 2039/505C07K 2317/74C07K 2317/56C07K 2317/92G01N 33/6872A61P 35/02C07K 16/2878G01N 33/56977G01N 33/575
78
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
Claims
exact text as granted — not AI-modified1 . An isolated monoclonal antibody, or antigen binding portion thereof, that specifically binds human CD137, wherein the antibody or antigen binding portion binds human CD137 with an affinity (K D ) of about 30-100 nM.
2 .- 103 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.